Back to top
more

Pacific Biosciences of California (PACB)

(Delayed Data from NSDQ)

$2.44 USD

2.44
10,605,080

+0.27 (12.44%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $2.45 +0.01 (0.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pacific Biosciences (PACB) Up 82.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pacific Biosciences (PACB) Catches Eye: Stock Jumps 6.6%

by Zacks Equity Research

Pacific Biosciences (PACB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Pacific Biosciences (PACB) Posts Lower-Than-Expected Q2 Loss

by Zacks Equity Research

Pacific Biosciences (PACB) saw revenue decline in both its operating segments in Q2.

Pacific Biosciences of California (PACB) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 21.05% and 23.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Pacific Biosciences of California (PACB) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pacific Biosciences (PACB) Up 8.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allscripts Unit Inks Deal to Boost Veradigm AccelRx Platform

by Zacks Equity Research

This deal is expected to bolster Allscripts' (MDRX) Clinical and Financial Solutions segment.

    Here's Why You Should Retain Masimo Stock (MASI) For Now

    by Zacks Equity Research

    Investor confidence remains high in Masimo (MASI) stock, thanks to solid prospects.

      Pacific Biosciences (PACB) Q1 Earnings Surpass Estimates

      by Zacks Equity Research

      Pacific Biosciences (PACB) saw revenue growth in the Service and Other segment in Q1.

      Varian (VAR) Earnings and Revenues Surpass Estimates in Q2

      by Zacks Equity Research

      Varian (VAR) continued to gain from core Oncology Systems segment in Q2.

      Luminex (LMNX) Q1 Earnings Miss Estimates, Revenues Beat

      by Zacks Equity Research

      Luminex's (LMNX) first-quarter earnings benefit from solid performance across Consumable Sales, Assay, Service and Other Revenues.

      CONMED (CNMD) Q1 Earnings and Revenues Surpass Estimates

      by Zacks Equity Research

      CONMED's (CNMD) first-quarter results gain from strong performance in General Surgery segment and expansion in margins.

      PRA Health (PRAH) Q1 Earnings and Revenues Beat Estimates

      by Zacks Equity Research

      PRA Health's (PRAH) Clinical Research segment puts up a strong performance in Q1.

      Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates

      by Zacks Equity Research

      Stryker's (SYK) first-quarter earnings gain from strong performance at MedSurg and Neurotechnology and Spine units.

      Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates

      by Zacks Equity Research

      Surmodics (SRDX) registered growth in one of its core units, Invitro Diagnostics, in Q2.

      ABIOMED (ABMD) Q4 Earnings Beat Estimates, Revenues Miss

      by Zacks Equity Research

      ABIOMED's (ABMD) flagship Impella saw decline in revenues within United States in Q4.

      Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates

      by Zacks Equity Research

      Baxter's (BAX) first-quarter earnings benefit from solid segmental performance and growth across all geographies.

      Will Pacific Biosciences of California (PACB) Report Negative Earnings Next Week? What You Should Know

      by Zacks Equity Research

      Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Accuray (ARAY) Earnings and Revenues Beat Estimates in Q3

      by Zacks Equity Research

      Accuray's (ARAY) gross orders were driven by solid EMEA momentum in Q3.

      Masimo (MASI) Q1 Earnings Beat Estimates, Margins Expand

      by Zacks Equity Research

      Masimo (MASI) sees solid growth in key Product segment in Q1.

      Here's Why You Should Retain Inogen (INGN) Stock for Now

      by Zacks Equity Research

      Investor confidence is high on Inogen (INGN) stock, thanks to solid prospects.

      Pacific Biosciences of California (PACB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

      by Zacks Equity Research

      Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Pacific Biosciences' Sequel II Gets Acquired by inqaba biotec

      by Zacks Equity Research

      Pacific Biosciences' (PACB) new development is likely to boost the company's flagship platform, the Sequel system.

      Why Is Pacific Biosciences (PACB) Down 18.1% Since Last Earnings Report?

      by Zacks Equity Research

      Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Can PennyMac (PFSI) Run Higher on Rising Earnings Estimates?

      by Zacks Equity Research

      PennyMac (PFSI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.